The antineoplastic activity of 4'-deoxydoxorubicin in murine solid tumors.
The antineoplastic effectiveness of 4'-Deoxydoxorubicin (DeDXR), a novel anthracycline with reduced cardiotoxicity, has been compared with that of Doxorubicin (DXR) in a panel of murine solid tumors of different histo-type, growth rate, and metastatic behaviour. Using doses of comparable toxicity and optimal treatment schedules, DeDXR was more active in the RC2 renal carcinoma, mFS6 fibrosarcoma, and Madison 109 carcinoma models, as judged by effects on primary and secondary tumor growth inhibition, increase in survival and/or proportion of tumor-free animals. In the M5076 reticulosarcoma DeDXR was equally effective with DXR, whereas the latter was more active on the PRSCT-5 prostate tumor.
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004317:Doxorubicin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D009374:Neoplasms, Experimental / Q000188:drug therapy* / Q000473:pathology
D000970:Antineoplastic Agents; D004317:Doxorubicin; C030851:esorubicin